drugset / Trial / NCT03545087
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment. Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.
Timeline
- Start
- 2018-06
- Primary completion
- 2019-01
- Completion
- 2019-01
Outcome
Outcome not reported
Stopped: “Stopped for futility. Phase 3 studies not likely to meet primary endpoints.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanabecestat | Small molecule | — | Oral |
| Background | Iohexol | Diagnostic / imaging agent | — | Intravenous |